Daiichi Sankyo completes pCPA negotiations enabling public reimbursement of Vanflyta across Canada
Daiichi Sankyo receives FDA approval for Datroway for first-line treatment of patients with metastatic triple negative breast cancer who are not PD-1/PD-L1 inhibitor candidates (¥2649.5000, 0)
StreetAccount Sector Summary - Healthcare Pre-Market
AstraZeneca's Enhertu recommended for approval in the EU by CHMP for patients with previously treated HER2-positive metastatic solid tumours (14008.0000p, +2)
EMA CHMP publishes summary of opinions for May 2026 meeting
EU's CHMP adopts positive opinion on Enhertu for patients with previously treated HER2 positive metastatic solid tumors (¥2649.5000, 0)
StreetAccount Sector Summary - Healthcare Post-Market
AstraZeneca's Enhertu approved in the US for two new indications for patients with HER2-positive early breast cancer (13632.0000p, 0)
Post-close news (Friday)
Powered by FactSet Research Systems Inc.